How Much Does Belsomra (Suvorexant) Cost in North Dakota in 2026?

Retail Cash-Pay Pricing Across North Dakota

The average cash-pay price for a 30-day supply of Belsomra at North Dakota retail pharmacies is approximately $85 per month in 2026. That figure sits well below the $340 manufacturer list price set by Merck, reflecting negotiated discounts and pharmacy benefit middlemen absorbing part of the spread.

Prices vary by pharmacy and city. Large chain pharmacies in Fargo and Bismarck tend to cluster near the state average, while independent pharmacies in smaller communities like Minot, Grand Forks, and Williston may charge $10 to $25 more per fill. Using a free discount card from GoodRx or RxSaver can sometimes push the out-of-pocket cost below $75 at select locations. The dose prescribed also matters: both the 10 mg and 20 mg tablets are priced identically by Merck, so dose escalation from 10 mg to 20 mg does not increase the per-tablet cost.

Suvorexant was approved by the FDA in August 2014 as the first dual orexin receptor antagonist (DORA) for insomnia. In the key phase III trial by Herring et al. (Lancet Neurology, 2014; N=3,291), suvorexant 20 mg reduced subjective time to sleep onset by approximately 8 minutes more than placebo at month 3, and improved total sleep time by roughly 16 minutes. That trial's wake-after-sleep-onset (WASO) data also showed a statistically significant improvement (P<0.001), confirming both onset and maintenance benefits.

No generic suvorexant exists yet. Merck's patent protection extends through 2029, which means North Dakota patients will not see lower-cost bioequivalent tablets for at least three more years.

North Dakota Medicaid Coverage: Not on the Preferred Drug List

North Dakota Medicaid does not cover Belsomra. The state's fee-for-service preferred drug list (PDL) excludes suvorexant from the covered sleep-aid formulary, favoring lower-cost alternatives such as generic zolpidem (approximately $5 to $15 per month) and generic eszopiclone.

Medicaid beneficiaries seeking Belsomra may file a prior authorization (PA) request through the North Dakota Department of Health and Human Services. Approval requires documented failure of, or medical contraindication to, at least two preferred formulary agents. In practice, approval rates for non-preferred DORAs under North Dakota Medicaid remain low. A 2023 analysis by the Medicaid and CHIP Payment and Access Commission (MACPAC) noted that state Medicaid programs increasingly restrict brand-name sleep medications when generic alternatives carry FDA-approved indications for the same condition.

Patients enrolled in North Dakota Medicaid Expansion (which covers adults with income up to 138% of the federal poverty level) face the same PDL restrictions. The Merck savings card cannot be applied to Medicaid prescriptions under federal anti-kickback statute rules.

Commercial Insurance Coverage in North Dakota

Most major commercial insurance plans available in North Dakota will cover Belsomra, but nearly all place it on a non-preferred brand tier (Tier 3 or Tier 4), which means higher copays and mandatory prior authorization.

Blue Cross Blue Shield of North Dakota (BCBSND), the state's largest private insurer, lists Belsomra on Tier 3 of its standard commercial formulary. The typical copay falls between $50 and $75 per month after prior authorization is granted. Sanford Health Plan, another major regional carrier, similarly requires PA and assigns Belsomra to its non-preferred brand tier with copays in the $40 to $80 range depending on the specific plan design.

Prior authorization criteria across most North Dakota insurers follow a common pattern:

• Diagnosis of insomnia disorder (ICD-10 G47.00 or G47.01)
• Documented trial and failure of at least one generic sleep medication
• Prescriber attestation that the patient does not have narcolepsy (suvorexant blocks the same orexin pathway that is already deficient in narcolepsy)

The American Academy of Sleep Medicine's 2017 clinical practice guideline lists suvorexant as a recommended pharmacotherapy for sleep maintenance insomnia in adults, which can support the clinical justification in a PA letter. Dr. Michael Sateia, lead author of that guideline, stated: "Suvorexant represents a mechanistically distinct option for patients who have not responded to, or cannot tolerate, benzodiazepine receptor agonists."

Employer-sponsored plans through national carriers (UnitedHealthcare, Aetna, Cigna) sold in North Dakota generally mirror their national formulary placement. Expect Tier 3 copays between $40 and $90 per month with PA.

How the Merck Savings Card Works in North Dakota

Merck offers the Belsomra Savings Card, which can reduce the out-of-pocket cost for commercially insured patients to as little as $0 per 30-day fill, up to a maximum annual benefit. The card is accepted at all major retail and mail-order pharmacies in North Dakota, including Walgreens, CVS, Thrifty White, and independent pharmacies.

Eligibility requirements are straightforward. Patients must have commercial (private) insurance that covers at least part of the Belsomra cost. The card cannot be used by patients enrolled in Medicare Part D, Medicaid, TRICARE, or any other federal or state government program. This restriction is mandated by the federal Anti-Kickback Statute and the Office of Inspector General's guidance on manufacturer copay assistance.

To activate the card, patients visit the Merck savings portal, enter their insurance information, and receive a digital or physical card with a BIN, PCN, and group number. The pharmacy processes it as a secondary claim after the primary insurance adjudicates. For a patient with a $60 Tier 3 copay, the savings card may reduce the remaining out-of-pocket amount to $0. The maximum benefit per prescription fill and per calendar year varies by program cycle; in 2026, the cap is typically $150 per fill.

Uninsured patients are not eligible for the standard savings card but may qualify for the Merck Patient Assistance Program (PAP), which provides Belsomra at no cost for patients with household income below 400% of the federal poverty level. That threshold equals $62,400 for a single individual in 2026.

Compounded Suvorexant: Legality and Access in North Dakota

Compounded suvorexant is available in North Dakota through 503A-licensed compounding pharmacies. These pharmacies operate under Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits patient-specific compounding based on a valid prescription.

North Dakota Board of Pharmacy regulations align with federal 503A standards. A compounding pharmacy must hold a valid North Dakota pharmacy license, compound from bulk drug substance or commercially available ingredients, and prepare the medication in response to an individual prescription. The North Dakota Century Code (Title 43, Chapter 43-15.3) governs compounding standards within the state and does not impose additional restrictions beyond federal requirements for 503A pharmacies.

Several 503A compounding pharmacies in the state and surrounding region (including pharmacies in Fargo, Bismarck, and mail-order operations based in neighboring states) offer compounded suvorexant. Pricing varies significantly. Some compounding pharmacies advertise compounded suvorexant capsules for substantially less than brand Belsomra, though the exact price depends on the compounding pharmacy's sourcing costs and formulation.

A critical distinction: compounded suvorexant is not FDA-approved and is not subject to the same bioequivalence testing as manufactured tablets. The FDA's 2022 guidance on 503A compounding emphasizes that compounded drugs should only be used when a commercially available product does not meet a patient's medical needs (e.g., allergy to an inactive ingredient, need for an alternative dosage form). Patients considering compounded suvorexant should discuss the tradeoffs with their prescriber.

Telehealth Prescribing of Belsomra in North Dakota

Suvorexant can be legally prescribed via telehealth in North Dakota. The state's telehealth parity law (North Dakota Century Code Section 26.1-36-09.15) requires insurers to cover telehealth services at the same rate as in-person visits, and the North Dakota Board of Medicine permits initial prescribing through audio-video telehealth encounters for non-controlled and Schedule IV controlled substances.

Belsomra is a Schedule IV controlled substance under both federal DEA classification and North Dakota law. Following the DEA's final rule on telehealth prescribing published in 2025, practitioners who hold a valid DEA registration and North Dakota medical license can prescribe suvorexant after a real-time audio-video evaluation. An in-person visit is not required for the initial prescription in most circumstances.

Several national telehealth platforms serve North Dakota patients for insomnia management. A typical telehealth consultation for insomnia costs between $75 and $200 for the initial visit without insurance. With insurance, copays generally match in-person specialist visit copays ($25 to $50 for most North Dakota commercial plans).

The American College of Physicians' 2016 clinical practice guideline recommends cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment before pharmacotherapy. Many telehealth platforms now integrate CBT-I modules alongside medication management, which may strengthen a prior authorization request for Belsomra by demonstrating that non-pharmacologic therapy alone was insufficient.

Comparing Belsomra to Other Sleep Medications Available in North Dakota

Belsomra's $85 average cash-pay price in North Dakota positions it in the mid-range among branded insomnia treatments. Generic zolpidem (Ambien) runs $5 to $15 per month. Generic eszopiclone (Lunesta) costs approximately $15 to $30. On the higher end, lemborexant (Dayvigo), a newer DORA also available in North Dakota, carries an average cash-pay price of approximately $380 to $420 per month.

The clinical comparison matters as much as cost. In a head-to-head polysomnography study (Vermeeren et al., 2019; N=58), suvorexant 20 mg and zolpidem ER 6.25 mg showed similar objective sleep-onset improvements, but suvorexant produced fewer next-morning psychomotor impairments on driving simulation tasks. The DORA mechanism blocks wakefulness-promoting orexin signaling rather than amplifying GABA-mediated sedation, which may explain the different residual-effect profile.

For North Dakota patients, the cheapest path to Belsomra follows this hierarchy:

1. Commercial insurance with Merck savings card (out-of-pocket as low as $0)
2. Merck Patient Assistance Program for uninsured or underinsured patients (free if eligible)
3. Cash-pay with a discount card at a high-volume pharmacy ($70 to $90)
4. Compounded suvorexant via a licensed 503A pharmacy (price varies by provider)

Dr. Andrew Krystal, a sleep researcher at UCSF and co-investigator on multiple DORA trials, has noted: "The orexin receptor antagonist class offers a different risk-benefit profile than traditional hypnotics, particularly regarding abuse liability and rebound insomnia."

Practical Steps to Lower Your Belsomra Cost in North Dakota

Start by confirming whether your insurance covers Belsomra and at which tier. Call the member services number on the back of your insurance card and request the formulary status and PA criteria for suvorexant. If PA is required, ask your prescriber's office to submit the authorization before sending the prescription to the pharmacy.

If approved, activate the Merck savings card and present it at the pharmacy along with your insurance card. The pharmacy technician processes your primary insurance first, then applies the savings card to the residual copay.

If your insurance denies coverage or you are uninsured, apply for the Merck Patient Assistance Program directly through the Merck Helps portal. Processing typically takes 4 to 6 weeks, so plan ahead and ask your prescriber for a short-term alternative or samples in the interim.

For patients paying cash, compare prices across at least three North Dakota pharmacies using a price-comparison tool. Mail-order pharmacies occasionally offer 90-day supplies at a per-unit discount of 10% to 15% compared to 30-day retail fills. Ask specifically about the 10 mg dose if you are new to suvorexant. The FDA-approved prescribing information recommends initiating at 10 mg nightly and increasing to 20 mg only if the lower dose is well tolerated but insufficiently effective, so starting at 10 mg does not change the monthly cost but may be adequate for many patients.